IBDEI0AJ ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4549,0)
 ;;=V10.83^^23^232^50
 ;;^UTILITY(U,$J,358.3,4549,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4549,1,4,0)
 ;;=4^V10.83
 ;;^UTILITY(U,$J,358.3,4549,1,5,0)
 ;;=5^H/O Skin Cancer
 ;;^UTILITY(U,$J,358.3,4549,2)
 ;;=H/O Skin Cancer^295241
 ;;^UTILITY(U,$J,358.3,4550,0)
 ;;=201.90^^23^232^60
 ;;^UTILITY(U,$J,358.3,4550,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4550,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,4550,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,4550,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,4551,0)
 ;;=200.20^^23^232^64
 ;;^UTILITY(U,$J,358.3,4551,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4551,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,4551,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,4551,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,4552,0)
 ;;=202.00^^23^232^66
 ;;^UTILITY(U,$J,358.3,4552,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4552,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,4552,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,4552,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,4553,0)
 ;;=200.10^^23^232^65
 ;;^UTILITY(U,$J,358.3,4553,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4553,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,4553,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,4553,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,4554,0)
 ;;=203.00^^23^232^77
 ;;^UTILITY(U,$J,358.3,4554,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4554,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,4554,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,4554,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,4555,0)
 ;;=203.01^^23^232^79
 ;;^UTILITY(U,$J,358.3,4555,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4555,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,4555,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,4555,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,4556,0)
 ;;=V10.21^^23^232^38
 ;;^UTILITY(U,$J,358.3,4556,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4556,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,4556,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,4556,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,4557,0)
 ;;=180.9^^23^232^8
 ;;^UTILITY(U,$J,358.3,4557,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4557,1,4,0)
 ;;=4^180.9
 ;;^UTILITY(U,$J,358.3,4557,1,5,0)
 ;;=5^Ca Cervix
 ;;^UTILITY(U,$J,358.3,4557,2)
 ;;=^267214
 ;;^UTILITY(U,$J,358.3,4558,0)
 ;;=203.02^^23^232^78
 ;;^UTILITY(U,$J,358.3,4558,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4558,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,4558,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,4558,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,4559,0)
 ;;=V10.91^^23^232^44
 ;;^UTILITY(U,$J,358.3,4559,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4559,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,4559,1,5,0)
 ;;=5^H/O Neuroendocrine CA Tumor
 ;;^UTILITY(U,$J,358.3,4559,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,4560,0)
 ;;=196.9^^23^232^62
 ;;^UTILITY(U,$J,358.3,4560,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4560,1,4,0)
 ;;=4^196.9
 ;;^UTILITY(U,$J,358.3,4560,1,5,0)
 ;;=5^Lymph Nodes
 ;;^UTILITY(U,$J,358.3,4560,2)
 ;;=^267313
 ;;^UTILITY(U,$J,358.3,4561,0)
 ;;=204.90^^23^232^63
 ;;^UTILITY(U,$J,358.3,4561,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4561,1,4,0)
 ;;=4^204.90
 ;;^UTILITY(U,$J,358.3,4561,1,5,0)
 ;;=5^Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,4561,2)
 ;;=^336854
 ;;^UTILITY(U,$J,358.3,4562,0)
 ;;=V10.82^^23^232^42
 ;;^UTILITY(U,$J,358.3,4562,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4562,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,4562,1,5,0)
 ;;=5^H/O Malig Melanoma
 ;;
 ;;$END ROU IBDEI0AJ
